Skip to content

The impact of phone-based reminder software app on medication adherence among hypertensive patients:a randomized clinical trial

The impact of phone-based reminder software on medication adherence among hypertensive patients: a randomized clinical trial

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
PACTR
Registry ID
PACTR202601612052478
Enrollment
120
Registered
2026-01-14
Start date
2025-11-10
Completion date
Unknown
Last updated
2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiology

Interventions

Medication reminder software
They will receive their usual care with no intervention

Sponsors

Dr. Ozomma Simon Izuchukwu
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Hypertensive patients 18years and above. Those owning smart phones who have adequate cognitive abilities to understand the use of software applications . Those who do not have co-morbidities that will prevent adherence measure . Those who give informed consent

Exclusion criteria

Exclusion criteria: Those who have co- morbidities that will prevent adherence measure Those who do not give informed consent to participate.

Design outcomes

Primary

MeasureTime frame
Improved adherence to medication after 6 months of using the app compared to control arm

Secondary

MeasureTime frame
Secondary out comes will be; Technology acceptance model, TAM, feasibility of intervention measure. Both will be determined using validated protocols, THE TAM AND FIM framework. Then the cost effectiveness of the intervention will be ascertained using the health related quality of life. Using EQ-5D-5L this captures five key dimensions of health, mobility, self care, usual care, pain/ discomfort and anxiety/ depression. The different health states will be converted to utility scores by applying Egypt's utility. This is relevant for calculate QALY that will enable determination of ICER. The ICER IS the difference in cost between the intervention and control divided by difference in QALY between the 2 groups. This will be compared to 0.17 times the GDP per capital of Nigeria to determine whether the intervention represents a cost effective venture. Findings will be reported using the cost effectiveness acceptability curve.

Countries

Nigeria

Contacts

Public ContactSimon Ozomma

Consultant Neurologist At University of Calabar teaching hospital Cross River state Nigeria

simonozomma@yahoomail.com+2348036694607

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026